Needham & Company LLC Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

Posted by Francis Steltz on Nov 4th, 2026

LivaNova (NASDAQ:LIVN – Get Free Report) had its target price upped by analysts at Needham & Company LLC from $93.00 to $112.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC‘s target price suggests a potential upside of 14.17% from the stock’s current price.

Several other research firms have also weighed in on LIVN. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Weiss Ratings upgraded LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 27th. Mizuho raised their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $90.12.

Get Our Latest Analysis on LIVN

LivaNova Trading Up 22.8%

NASDAQ:LIVN traded up $18.20 on Wednesday, reaching $98.10. 1,770,677 shares of the stock traded hands, compared to its average volume of 735,428. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 28.98 and a beta of 0.91. The company’s 50 day moving average is $78.56 and its 200-day moving average is $73.10. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova has a 1-year low of $48.82 and a 1-year high of $98.13.

LivaNova (NASDAQ:LIVN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $393.10 million during the quarter, compared to analysts’ expectations of $381.13 million. During the same period in the prior year, the company posted $1.11 earnings per share. LivaNova’s revenue for the quarter was up 9.9% compared to the same quarter last year. Equities research analysts anticipate that LivaNova will post 3.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the sale, the director owned 7,488 shares in the company, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,450 shares of company stock worth $591,839 over the last quarter. Company insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LIVN. Allworth Financial LP lifted its position in LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. Root Financial Partners LLC purchased a new stake in LivaNova during the third quarter valued at about $32,000. Farther Finance Advisors LLC raised its position in LivaNova by 59.7% during the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock valued at $35,000 after purchasing an additional 169 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in LivaNova during the second quarter worth about $37,000. Finally, Sterling Capital Management LLC boosted its holdings in shares of LivaNova by 34.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,261 shares of the company’s stock worth $96,000 after purchasing an additional 324 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Key Headlines Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

Positive Sentiment: Q3 adjusted earnings were $1.23 per share, ahead of analyst estimates of roughly $1.03–$1.06 and up from $1.11 a year earlier. LivaNova Surpasses Q3 Earnings and Revenue Estimates
Positive Sentiment: Revenue rose 9.9% year over year to $393.1 million, exceeding estimates of about $381 million. LivaNova delivers Q3 revenue of $393.1M, up 9.9%
Positive Sentiment: The company raised its full-year EPS guidance, adding to the earnings beat as a potential support for investor expectations. The articles provided did not specify the revised guidance range. LivaNova beats Q3 2026 estimates and raises full-year EPS guidance

LivaNova Company Profile

(Get Free Report)

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.